Novavax to Host Conference Call to Discuss Second Quarter Financial and Operating Results on August 10, 2020

Rhea-AI Summary

Novavax, a late-stage biotechnology company, will release its second quarter 2020 financial results on August 10, 2020, after U.S. market close. The conference call is scheduled for 4:30 p.m. ET, with dial-in numbers provided for domestic and international participants. The call will cover latest updates on Novavax's vaccine candidates, including NVX-CoV2373 for COVID-19 and NanoFlu, their influenza vaccine. Investors can access a webcast of the call and a replay available until August 17, 2020.

GAITHERSBURG, Md., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its second quarter 2020 financial and operating results following the close of U.S. financial markets on Monday, August 10, 2020.

Conference call details are as follows:

Date:	August 10, 2020
Time:	4:30 p.m. U.S. Eastern Time (ET)
Dial-in number:	(877) 923-9376 (Domestic) or (720) 545-0026 (International)
Passcode:	3048947
Webcast:	www.novavax.com, “For Investors”/ “Events”

Conference call and webcast replay:

Dates:	Starting at 7:30 p.m. ET, August 10, 2020 until 7:30 p.m. ET August 17, 2020
Dial-in number:	(855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode:	3048947
Webcast:	www.novavax.com, “For Investors”/ “Events”, until November 10, 2020

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax is undergoing clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NVX‑CoV2373 was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in its Phase 1 portion of the Phase 1/2 clinical trial. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.

For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.

Investors
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022

Media
Amy Speak
amy@speaklifescience.com
617-420-2461

 

FAQ

When will Novavax report Q2 2020 financial results?

Novavax will report its Q2 2020 financial results on August 10, 2020.

What time is the Novavax conference call on August 10, 2020?

The conference call is scheduled for 4:30 p.m. U.S. Eastern Time.

How can I access the Novavax conference call?

You can access the call by dialing (877) 923-9376 domestically or (720) 545-0026 internationally.

What is NVAX's vaccine candidate for COVID-19?

Novavax's vaccine candidate for COVID-19 is NVX-CoV2373.

Until when is the conference call replay available?

The replay of the conference call will be available until August 17, 2020.